Business Wire

Regulators Approve Impella 5.5 With SmartAssist in Japan and Hong Kong; US FDA Grants Impella BTR Conditional IDE Approval for First-in-Human Early Feasibility Study

Share

Regulators in three countries have granted approvals to Impella surgical products, as Abiomed (NASDAQ: ABMD) continues to execute its strategy for sustainable growth with new products, new indications and new geographies. In the United States, the Food and Drug Administration (FDA) has granted an Early Feasibility Study (EFS) Investigational Device Exemption (IDE) to Impella BTR (Bridge-to-Recovery). In Asia, Impella 5.5 with SmartAssist has received approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) and Hong Kong’s Medical Device Division (MDD).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220110005312/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Impella 5.5 with SmartAssist is now approved for use in Japan and Hong Kong. (Graphic: Business Wire)

Impella 5.5 with SmartAssist is a game-changing technology for patients in Japan and Hong Kong. It is a minimally invasive, forward flow, fully unloading heart pump designed by and for heart surgeons with direct or axillary insertion. It received FDA post-market approval (PMA) two years ago. Since then, it has been used to treat more than 4,000 US patients for indications that include AMI cardiogenic shock, cardiomyopathy and post-cardiotomy cardiogenic shock. Historically, the cardiogenic shock survival rate has been approximately 50%. Impella 5.5 with SmartAssist patients have a 74% survival to explant, with 59% of surviving patients achieving native heart recovery.

In Japan, Impella 5.5 with SmartAssist is now indicated for use in the treatment of drug-resistant acute heart failure attributable to causes such as cardiogenic shock. The first Impella 5.5 with SmartAssist patient in Japan is expected to be treated in the coming months.

“The Japanese market is ideal for Impella 5.5 with SmartAssist because the technology provides minimally invasive, longer-term unloading support, enabling native heart recovery in a country that is more resistant to invasive sternotomies and heart transplants,” said Michael R. Minogue, Abiomed’s Chairman, President and Chief Executive Officer.

In the United States, the FDA has approved the Impella BTR early feasibility IDE study, clearing the way for the first patient in the world to be treated with Impella BTR. Impella BTR is a percutaneous heart pump, with greater than six liters of blood flow per minute. It is designed to be much less invasive than current LVADs.

The vision of the Impella BTR development program is to provide a patient with home discharge and up to one year of full hemodynamic support. In the early feasibility study, ten patients will be enrolled at up to five hospitals and supported by Impella BTR for up to 28 days. The first Impella BTR patient is expected to be treated in March or April this year.

“The FDA’s approval is a first step toward making this longer-term minimally invasive forward flow smart heart pump a reality for patients with chronic heart failure,” said Minogue.

Impella BTR is an investigational device, limited by federal law to investigational use only.

ABOUT IMPELLA HEART PUMPS

The Impella 2.5® and Impella CP® devices are US FDA approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI), such as stenting or balloon angioplasty, to reopen blocked coronary arteries.

Impella 2.5, Impella CP, Impella CP with SmartAssist®, Impella 5.0®, Impella LD®, and Impella 5.5® with SmartAssist® are US FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.

Impella BTR® is an investigational device, limited by federal law to investigational use only.

ABOUT ABIOMED

Based in Danvers, Massachusetts, USA, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: www.abiomed.com.

FORWARD-LOOKING STATEMENTS

Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information please contact:

Media Contact:
Tom Langford
Director of Communications
+1 (978) 882-8408
tlangford@abiomed.com

Investor Contact:
Todd Trapp
Vice President and Chief Financial Officer
+1 (978) 646-1680
ttrapp@abiomed.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corona Spearheads Eco-Tourism with Corona Island, the World’s First Blue Verified, Single-Use Plastic-Free Island9.8.2022 13:11:00 CEST | Press release

Today, global beer brand Corona announces the grand opening of Corona Island, a tropical sustainable destination for eco-tourism off the coast of Colombia. A first-of-its-kind island paradise, Corona Island is free of single-use plastic, encouraging guests to reconnect with the natural world through immersive hospitality experiences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220809005308/en/ Corona Island (Photo: Business Wire) As a beer made with natural ingredients that was born at the beach and the first global beverage brand with a net-zero plastic footprint*, Corona partnered with international nonprofit Oceanic Global to create the first Blue Verified island. Corona Island has achieved Oceanic Global’s three-star plastic-free Blue Seal for eliminating single-use plastic and adopting sustainable operating best practices at scale. From construction to energy production, food sourcing and guest experiences on-site, s

Q4 Inc. Announces Appointment of Chief Financial Officer9.8.2022 13:00:00 CEST | Press release

Q4 Inc. (TSX: QFOR), a leading capital markets communications platform, today announced the appointment of Donna de Winter as chief financial officer (CFO) effective August 8, 2022. Ms. de Winter has been serving as interim CFO since May 31, 2022. “On behalf of the Q4 Board and the entire Q4 team, we are thrilled to announce that Donna has assumed the role of CFO, after serving in an interim capacity for the last few months,” said Darrell Heaps, CEO. “We are incredibly fortunate to benefit from Donna’s breadth of industry expertise across finance, strategy and operations. Donna has added tremendous value to Q4 over the last few years as Chief Operating Officer, and her lens of operational knowledge along with her strong background as a financial leader of both private and publicly traded companies brings a powerful combination and perspective to the CFO role. We look forward to benefiting from Donna’s deep bench of experience as we pursue our strategic vision and path to profitability.

Aria Systems to Showcase TM Forum Catalyst Solution at Digital Transformation World9.8.2022 13:00:00 CEST | Press release

Aria Systems, the leader in helping enterprises grow subscription and usage-based revenue, today announced the company will be at Digital Transformation World (DTW) in September to present the findings and solution resulting from its involvement in one of TM Forum’s most championed catalyst programs. Aria and its partners have been exploring how an event-driven architecture can enable service providers to build more scalable and flexible IT architecture with lower integration costs, and faster time to market. Catalysts are proof-of-concept projects developed collaboratively by members to solve problems presented by leading global communications service providers (CSPs) and define and propose new industry standards. Together with its partners and CSP champions, Aria will demonstrate how the Open Digital Framework (ODF) can be enhanced for organizations that have adopted a modern event-driven architecture. “As CSPs transform their BSS solution with best-of-breed capabilities to support n

Ferring Announces U.S. FDA Advisory Committee Meeting for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic9.8.2022 13:00:00 CEST | Press release

Ferring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) will hold a meeting on September 22, 2022, to review data supporting the biologics license application (BLA) for RBX2660, a microbiota-based live biotherapeutic studied for its potential to reduce recurrent C. difficile infection (CDI) after antibiotic treatment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220809005214/en/ “The gut microbiome is a highly diverse community of microbes that plays an essential role in human health. Emerging research has shown the promise of leveraging the microbiome to address a range of conditions, including serious diseases such as recurrent C. difficile infection,” said Elizabeth Garner, Chief Scientific Officer, Ferring Pharmaceuticals, U.S. “The cycle of recurrent CDI represents a significant public health burden, and Ferrin

MarineMax To Acquire IGY Marinas Significantly Expanding Global Marina and Services Business9.8.2022 12:45:00 CEST | Press release

MarineMax, Inc. (NYSE: HZO), the world’s largest recreational boat and yacht retailer, today announced that it has entered into a definitive agreement to acquire Island Global Yachting LLC (“IGY Marinas”), which owns and operates a collection of iconic marina assets and a yacht management platform in key global yachting destinations. MarineMax will acquire IGY Marinas for $480 million in cash, with an additional potential earnout of up to $100 million two years after closing, subject to the achievement of defined performance metrics. IGY Marinas, through recent acquisitions and organic growth, is projected to generate over $100 million of revenue in calendar 2022. Subject to the satisfaction of customary closing conditions, MarineMax expects the acquisition to close in the first half of fiscal 2023 and to be accretive within the first twelve months of closing. IGY Marinas will maintain its luxury branding that is well recognized as best-in-class in the global marina and superyacht comm

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom